These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23960448)

  • 1. Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
    Park J; Song JH; Park DA; Lee JS; Lee SD; Oh YM
    J Korean Med Sci; 2013 Aug; 28(8):1200-6. PubMed ID: 23960448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
    He B; Zhang F; Li X; Tang C; Lin G; Du J; Jin H
    Circ J; 2010 Jul; 74(7):1458-64. PubMed ID: 20519876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
    Maxey DM; Ivy DD; Ogawa MT; Feinstein JA
    Pediatr Cardiol; 2013 Oct; 34(7):1628-36. PubMed ID: 23532466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
    BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan for the treatment of portopulmonary hypertension.
    Tempe DK; Datt V; Datta D
    Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulmonary arterial hypertension: combination therapy in the modern management era.
    Sitbon O
    Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
    [No Abstract]   [Full Text] [Related]  

  • 8. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
    Hoeper MM
    Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
    Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
    Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of secondary pulmonary hypertension.
    Maloney JP
    Curr Opin Pulm Med; 2003 Mar; 9(2):139-43. PubMed ID: 12574694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of targeted therapies for pulmonary hypertension in children.
    Roldan T; Deiros L; Romero JA; Gutierrez-Larraya F; Herrero A; Del Cerro MJ
    Pediatr Cardiol; 2014 Mar; 35(3):490-8. PubMed ID: 24141893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bosentan and chronic thromboembolic pulmonary hypertension].
    Tomás C; Callejas-Rubio JL; Ríos-Fernández R; Ortego-Centeno N
    Med Clin (Barc); 2007 Nov; 129(16):639. PubMed ID: 18001681
    [No Abstract]   [Full Text] [Related]  

  • 16. Sildenafil for pulmonary hypertension: need for evidence generation.
    Shafiq N; Reddy S; Pandhi P; Manoj R; Talwar KK; Malhotra S
    Int J Clin Pharmacol Ther; 2008 Dec; 46(12):644-51. PubMed ID: 19049698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
    Mittoo S; Jacob T; Craig A; Bshouty Z
    Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.
    Minniti CP; Machado RF; Coles WA; Sachdev V; Gladwin MT; Kato GJ
    Br J Haematol; 2009 Dec; 147(5):737-43. PubMed ID: 19775299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
    Krishnan U; Krishnan S; Gewitz M
    Pediatr Cardiol; 2008 Nov; 29(6):1082-6. PubMed ID: 18594787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pulmonary arterial hypertension.
    Ricachinevsky CP; Amantéa SL
    J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S153-65. PubMed ID: 17136291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.